Lower Risk of Cardiovascular Death with Tirzepatide in Heart Failure
The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 68 results for 'tirzepatide'
FDA Says Shortage of GLP-1 Tirzepatide Is Over
THURSDAY, Dec. 19, 2024 (HealthDay News) — The U.S. Food and Drug Administration re-issued a...
Read More
SUMMIT: Tirzepatide Reduces Cardiovascular Events in HFpEF Plus Obesity
In the phase 3 SUMMIT trial, tirzepatide, was found to reduce the risk for worsening heart failure in patients with preserved ejection fraction and obesity.
Read More
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
MONDAY, Nov. 18, 2024 (HealthDay News) — For patients with obesity and prediabetes, three...
Read MoreEffects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular-kidney end-organ damage. In the SUMMIT trial,...
Read More
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) — Pharmacists may continue making compounded...
Read More
Tirzepatide reduces obstructive sleep apnea symptoms and associated risks
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep...
Read More
Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
MONDAY, Aug. 12, 2024 (HealthDay News) — For patients with type 2 diabetes, treatment with...
Read More
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 (HealthDay News) — Tirzepatide is associated with significantly greater...
Read MoreAdvertisement
#VisualAbstract: Tirzepatide Improved Outcomes in Patients with Obstructive Sleep Apnea and Obesity
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index...
Read More
#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 (HealthDay News) — For patients with metabolic...
Read More
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 (HealthDay News) — Among slow responders to tirzepatide treatment at...
Read More
Eli Lilly: Tirzepatide Shows Promise In Treating Obstructive Sleep Apnea In Two Phase 3 Clinical Trials
Tirzepatide lead to a 63% mean reduction in restricted/obstructed breathing events per hour in...
Read More
Analysis of Tirzepatide Efficacy in Hispanic/Latino Patients With T2D
The following is a summary of “Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes:...
Read More
Tirzepatide Improves 24-Hour BP in Obesity-Related Hypertension
WEDNESDAY, Feb. 7, 2024 (HealthDay News) — For patients with obesity and hypertension,...
Read More
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
MONDAY, Dec. 11, 2023 (HealthDay News) — Withdrawing tirzepatide after 36 weeks is...
Read More
Exploring the Impact of Weight Reduction on Blood Pressure in Individuals with Obesity Under Tirzepatide Treatment
The following is a summary of “Does Weight Reduction Drive the Reduction in Blood Pressure...
Read More
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
WEDNESDAY, Nov. 8, 2023 (HealthDay News) — Tirzepatide provides substantial additional...
Read More